Topic: non-Hodgkin lymphoma
To show Brukinsa is better than AbbVie and J&J's blockbuster Imbruvica, BeiGene is running phase 3 head-to-head trials in blood cancers.
Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.
The nod comes as Celgene and Roche are looking to add new indications to their old cancer stalwarts.
Chinese authorities have approved Fosun subsidiary Henlius' Rituxan copycat, the country's first biosimilar.
Payer coverage is key to Novartis’ plan to get Kymriah going, and the company is going to be getting some more of that.
All eyes are on Roche as the first biosimilar rival to big-selling lymphoma blockbuster Rituxan won FDA approval.
The first dual PI3K-delta/gamma inhibitor will go up against Gilead's Zydelig, the first PI3K inhibitor, and Bayer’s Aliqopa.